Evidence platform
Explore cohorts, outcomes, and study scenarios in one workspace.
Inspect licensed cohorts, compare outcomes, test study scenarios, and export summaries in one workspace.
Outcomes
Scenario comparison
Guided product tour
From cohort selection to sponsor review.
- 01
Select cohort
Choose the indication and evidence context available to the account.
- 02
Review fit
Review population, variables, endpoints, completeness, and follow-up.
- 03
Compare outcomes
Interrogate effectiveness, safety, and patient subgroups.
- 04
Test scenarios
Evaluate implications for trial design or control strategy.
- 05
Export summary
Export sponsor-ready summaries and engage Evinexus scientists.
Outcomes exploration
Inspect response and safety results alongside the underlying counts.
Compare objective response and adverse-event rates across arms, with every percentage and interval traceable back to the counts and population it was computed from.
Illustrative example — tumor response & safety
Treatment arm · ORR
35.9%
214 / 596 evaluable
Control arm · ORR
25.8%
141 / 546 evaluable
Response risk ratio
1.39
treatment vs. control
Median duration of response
NA
Best overall response
Complete response (CR)
Partial response (PR)
Stable disease (SD)
Progressive disease (PD)
Adverse events
Safety population: 1142 · Any-grade AE rate: 84.8%
| Adverse event | n | % (95% CI) |
|---|---|---|
| Fatigue | 498 | 43.6% (40.7–46.5) |
| Nausea | 431 | 37.7% (34.9–40.6) |
| Anaemia | 387 | 33.9% (31.1–36.7) |
| Neutropenia | 349 | 30.6% (27.9–33.3) |
| Diarrhoea | 302 | 26.4% (23.9–29.1) |
| Decreased appetite | 276 | 24.2% (21.7–26.8) |
| Pyrexia | 241 | 21.1% (18.8–23.6) |
| Vomiting | 219 | 19.2% (16.9–21.6) |
Tumor response and adverse-event rates by arm — illustrative example, not a validated result.
Platform + services
Self-directed exploration with expert support available.
Licensed platform access
Named sponsor teams explore the digital twin data available under their program license.
Scientific partnership
Evinexus supports complex analysis, interpretation, study delivery, and regulatory engagement.
Review a study question in the platform.
Licensed sponsor teams use the platform within their program access. Prospective customers see it in a representative-led demonstration.